EMA Authorised: Alhemo (concizumab) — Novo Nordisk A/S

View source ↗

Summary

EMA authorised Alhemo (concizumab) by Novo Nordisk A/S for the treatment of hemophilia A and hemophilia B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ALHEMO (Concizumab)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A;Hemophilia B. MAH: Novo Nordisk A/S. Decision date: 22/08/2025